Licensed 4CMenB vaccine — Competitive Intelligence Brief

Licensed 4CMenB vaccine (Licensed 4CMenB vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein vaccine. Area: Immunology / Infectious Disease.

marketed Recombinant protein vaccine Neisseria meningitidis serogroup B surface antigens Immunology / Infectious Disease Biologic

Target snapshot

Licensed 4CMenB vaccine (Licensed 4CMenB vaccine) — University of Adelaide. 4CMenB is a recombinant meningococcal serogroup B vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Licensed 4CMenB vaccine TARGET	Licensed 4CMenB vaccine	University of Adelaide	marketed	Recombinant protein vaccine	Neisseria meningitidis serogroup B surface antigens
Meningococcal B	Meningococcal B	Canadian Immunization Research Network	marketed	vaccine	Neisseria meningitidis serogroup B surface antigens (recombinant proteins)
rMenB+OMV NZ vaccine	rMenB+OMV NZ vaccine	GlaxoSmithKline	marketed	Meningococcal serogroup B vaccine	Neisseria meningitidis serogroup B surface antigens
Bexsero® vaccine	Bexsero® vaccine	ANRS, Emerging Infectious Diseases	phase 3	Recombinant protein vaccine	Neisseria meningitidis serogroup B surface antigens (fHbp, NHBA, NadA, PorA)
MenBvac	MenBvac	University Hospital, Rouen	phase 3	Vaccine	Neisseria meningitidis serogroup B surface antigens
Meningococcal vaccine GSK134612	Meningococcal vaccine GSK134612	GlaxoSmithKline	phase 3	Recombinant protein vaccine	Neisseria meningitidis serogroup B surface antigens
Meningococcal B (Bexsero)	Meningococcal B (Bexsero)	University of Sao Paulo General Hospital	marketed	Recombinant protein vaccine	Meningococcal serogroup B surface antigens (recombinant Neisseria meningitidis proteins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein vaccine class)

1. GlaxoSmithKline · 6 drugs in this class
2. Novavax · 5 drugs in this class
3. Vaxine Pty Ltd · 2 drugs in this class
4. D'Or Institute for Research and Education · 2 drugs in this class
5. Protein Sciences Corporation · 2 drugs in this class
6. Henogen · 1 drug in this class
7. Henry M. Jackson Foundation for the Advancement of Military Medicine · 1 drug in this class
8. Institut National de la Santé Et de la Recherche Médicale, France · 1 drug in this class
9. National Vaccine and Serum Institute, China · 1 drug in this class
10. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 drug in this class